AzTrials
AzTrials

PeriodontitisSFA-SDNCT06897085

Efficacy of a Gel Containing Polynucleotides and Hyaluronic Acid in Supraosseous Periodontal Defects Treated with the Single Flap Approach

A study testing viscoelastic gel containing polynucleotides and hyaluronic acid in people with Periodontitis and Gingival Recession, Localized, run by Azienda Unità Sanitaria Locale (A.U.S.L.) Ferrara, Italy.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Official record
Search all trials

Trial summary

Treatment of supraosseous defects (SD) may be challenging due to their limited regenerative potential. When located in aesthetic areas, treatment may result in a gingival recession increase with consequent patients' concerns in terms of aesthetic or tooth sensibility. Read more about this study

Who is it for?
Any age
What is being tested?
viscoelastic gel containing polynucleotides and hyaluronic acid
Type of treatment
Medical device
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
70 participants
Where
No sites listed yet
Study dates
1 Apr 2025to 30 Dec 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • age≥ 18 years;
  • diagnosis of Stage III or IV periodontitis22;
  • good physical status (ASA1 and ASA2 according to Physical Status Classification System);
  • systemic and local conditions compatible with periodontal surgical procedures;
  • patient willing and fully capable to comply with the study protocol.
  • Site-specific
Show all 9Show fewer
  • defect located in an incisor, canine or premolar region which becomes exposed during spontaneous smiling;
  • defect with an intrabony component (as assessed on periapical radiograph and confirmed intra-surgically) ≤ 2 mm;
  • defect with a radiographic CEJ-BC≥ 4 mm; d) residual (following step I-II of treatment) PD≥6 mm at both interproximal aspects facing the SD.

Who cannot join

  • poorly controlled diabetes (HbA1C ≥ 7%);
  • history of radiation therapy in the head and neck area;
  • history of chemotherapy;
  • systemic disease or conditions with a documented effect on bone metabolism and/or periodontal status/healing;
  • past (within 6 months prior to enrollment in the study) or current treatment with any medication with a documented effect on bone metabolism and/or periodontal status/healing;
  • physical or mental handicap that can interfere with adherence to the study procedures and adequate hygienic compliance;
Show all 19Show fewer
  • documented allergy to dental materials involved in the experimental protocol;
  • pregnancy or lactation;
  • history of drug or alcohol abuse.
  • Moreover, participants will be immediately excluded from the study:
  • upon request to withdraw from further participation;
  • development of acute dental/periodontal or oral conditions requiring treatment;
  • development of conditions conflicting with the exclusion criteria listed above
  • failure to comply with study instructions/requirements.
  • Site-specific
  • presence of untreated endodontic lesions or inadequate endodontic treatment of teeth facing the SD;
  • presence of orthodontic appliances;
  • local conditions preventing proper plaque control at experimental sites;
  • grade III mobility.

About this study

Official title: Efficacy of a Gel Containing Polynucleotides and Hyaluronic Acid in the Treatment of Periodontal Supraosseous Defects with the Single Flap Approach: a Randomized Controlled Trial

Treatment of supraosseous defects (SD) may be challenging due to their limited regenerative potential. When located in aesthetic areas, treatment may result in a gingival recession increase with consequent patients' concerns in terms of aesthetic or tooth sensibility. In the present study, a minimally-invasive surgical procedure (namely, the Single Flap Approach, SFA) will be combined with the application of a viscoelastic gel containing polynucleotides and hyaluronic acid that was reported to positively modulate periodontal wound healing. The outcomes, evaluated 6 months after treatment, will be compared to those obtained with SFA alone. The evaluated outcomes will be either clinical (evaluation of clinical parameters such as gingival recession, residual probing depth, clinical attachment gain) or related to patient's perception (such as evaluation of the aesthetic or tooth sensibility).

Read the detailed description

SDs have been indicated as the most challenging lesions when dealing with periodontal regenerative procedures. In fact, their non-containing morphology does not contribute wound stability, and the wound maturation phase does not benefit from the cellular support coming from residual lateral bony walls, as in intraosseous defects. Also, the absence of residual bony walls does not allow a proper support of the surgical flaps, thus reducing the space needed for regeneration. Because of this unfavorable morphology, treatment of SDs generally results in worse clinical outcomes compared to intraosseous defects. Nevertheless, noteworthy clinical results have been reported when SDs associated to moderate or deep PD were treated with open flap debridement alone. In a systematic review Graziani et al. (2014), showed mean PD reductions of 1.41 mm in sites of moderate pre-surgical pocket depth (i.e., mean PD of 5.19 mm) that reached mean residual pockets of 3.83 mm over 6 months after treatment. More recently, a high prevalence of closed pockets (i.e., 79.3% of sites with residual PD ≤ 3mm) have been reported 12 months after treatment of deep (i.e., mean presurgical value of 6.3 ±0.6 mm) sites with access flap based on papilla preservation techniques (i.e., Modified/Simplified Papilla Preservation Technique).

In 2021, the Single Flap Approach (SFA), a surgical technique originally introduced in the treatment of intraosseous defects, have been also proposed for SDs. The basic principle underlying the SFA is the elevation of a single flap (i.e., on the buccal or oral aspect only, depending on the main extension of the defect) to access the defect, leaving the interproximal supracrestal soft tissue intact. Data stemming from a retrospective analysis showed that the SFA with or without EMD was similarly effective in the treatment deep bleeding pockets associated to a horizontal pattern of bone destruction. In the study arm receiving SFA as a stand-alone protocol, significant mean CAL gains (2.1± 0.9 mm) and PD reductions (3.1± 1.0 mm) were observed 12 months after therapy. These results appear similar or even superior when compared to those reported by other studies where SDs were accessed with Double Flap Approach (based on Papilla Preservation Techniques) alone. Interestingly, this observation has been confirmed by a recent study where clinical and radiographic outcomes observed after surgical access of SDs performed by either a SFA or a DFA were compared. At 6 months, treatment with SFA resulted in greater prevalence of sites reaching CAL gain ≥ 1mm (80% vs 11%) and PD≤ 3mm (40% vs 10%) compared to DFA, thus suggesting that SFA principles may lead to improved clinical outcomes compared to DFA even in the treatment of SDs.

Although the evidence from previous studies support the SFA as a promising treatment for SDs, some clinical aspects currently need further investigation. In the study by Simonelli et al. (2021), a tendency to suboptimal wound closure was evident, with 30% of defects undergoing SFA alone showing Early Healing Index (EHI) scores of 4 or 5 at 2 weeks after surgery. Based on data coming from a previous study demonstrating a trend towards better clinical outcomes (greater CAL gain, less buccal REC increase) in defects with optimal wound closure compared to incomplete wound closure, we may hypothesize that this aspect could have negatively influenced the observed clinical results. In fact, 1-year CAL gain (2.1 mm) was limited if compared to pre-surgery CAL (7.5 mm), and a mean gingival recession (REC) increase of 1 mm was observed.

Recently, a viscoelastic gel containing polynucleotides and hyaluronic acid (PN-HA) was shown to positively influence the viability and proliferation of gingival fibroblasts, thus representing a plausible candidate as periodontal wound modulator. These in vitro results had been partially confirmed by a clinical study where the use of a PN-HA gel showed a higher tendency to pocket closure after subgingival re-instrumentation of PD≥ 5 mm. To date, no clinical data on the effectiveness of PN-HA gel after surgical treatment of SDs is available.

Primary aim The primary aim of the study will be to evaluate the superiority of SFA + PN-HA gel over SFA for the change in interproximal gingival recession (iREC) observed 6 months after surgery of SDs in esthetic areas.

Secondary aims The secondary aims of the study will be to comparatively evaluate SFA + PN-HA gel and SFA for the (i) 6-month prevalence of closed, non-bleeding pockets (i.e., PD≤ 4mm); (ii) quality of early wound closure; (iii) 6-month CAL gain; (iv) 6-month change in buccal gingival recession (bREC); (v) 6-month change in radiographic defect depth; (vi) duration of the surgical procedure; (vii) PROMs, including adverse events, postoperative pain intensity/duration, and patient satisfaction.

Being tested
viscoelastic gel containing polynucleotides and hyaluronic acid, No intervention
Keywords
minimally invasive, single flap approach
Medical subject headings
Periodontitis, Gingival Recession

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • viscoelastic gel containing polynucleotides and hyaluronic acidDevice

    Defects randomized to "test treatment" will receive a viscoelastic gel containing polynucleotides and hyaluronic acid (PN-HA gel) immediately at the completion of intra-surgical instrumentation. PN-HA gel will be also applied on the surgical wound at the completion of the suturing phase.

  • No interventionOther

    Defects randomized to "control group" will be accessed with the SFA and no PN-HA gel will be applied.

Study groups in NCT06897085
Study groupRoleWhat they receive
Single Flap Approach (SFA) plus gel containing polynucleotides and hyaluronic acid (PN-HA)ExperimentalDefects treated in this study arm will receive a surgical intervention based on the SFA and will receive the application of PN-HA gel at the completion of defect debridement.
Receives: Device: viscoelastic gel containing polynucleotides and hyaluronic acid
Single Flap Approach (SFA) aloneSham comparatorDefects will receive a surgical intervention based on SFA alone (no PN-HA gel will be addedd)
Receives: Other: No intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Interproximal gingival recession (iREC)

    the primary outcome of the study will be iREC change

    Measured: 6 months after surgical treatment of supraosseous defects

Secondary outcomes (6)
  1. Prevalence of closed, non bleeding pockets

    closed pocket (i.e., residual 6-month probing depth (PD)≤ 4mm)

    Measured: 6 months after surgical treatment

  2. Quality of early wound closure

    The quality of early wound closure will be evaluated using the "early healing index" (EHI), as proposed by Wachtel et al. in 2003.

    EHI is based on the following scale: (EHI=1) complete flap closure, no fibrin line in the interproximal area; (EHI=2) complete flap closure, fine fibrin line in the interproximal area; (EHI=3) complete flap closure, fibrin clot in the interproximal area; (EHI=4) incomplete flap closure, partial necrosis of the interproximal tissue; and (EHI=5) incomplete flap closure, complete necrosis of the interproximal tissue.

    Measured: 2-week follow-up

  3. Clinical Attachment Level (CAL) Gain

    6-month CAL gain will be calculated by subtracting the 6-month CAL value from the baseline CAL

    Measured: 6 months after surgical treatment

  4. Change in buccal gingival recession (bREC);

    bREC change will be calculated by subtracting the 6-month bREC value from the baseline bREC value

    Measured: 6 months after surgical treatment

  5. Change in radiographic defect depth

    change in radiographic defect depth will be calculated by subtracting the 6-month radiographic defect depth value from the baseline radiographic defect depth value

    Measured: 6 months after surgical treatment

  6. PROMs

    PROMs will include adverse events, postoperative pain intensity/duration, and patient satisfaction.

    Both "postoperative course" and "patient satisfaction" will be assessed through a self-administered questionnaire and/or a VAS (1-100) ranging from "0 - no pain/no satisfaction" to "100 - intolerable pain/full satisfaction".

    Measured: post-operative days 1, 2, 7 and 14

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Mar 2025
  2. Study start1 Apr 2025 (estimated)
  3. Primary completion30 Dec 2026 (estimated)
  4. Study completion30 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Investigator, Outcomes assessor
Enrolment
70 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06897085
Sponsor's protocol ID
7359
Other IDs
Osteology Foundation
Acronym
SFA-SD
Status last verified
Mar 2025
First submitted
20 Mar 2025
Last updated
1 Apr 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Graziani F, Gennai S, Cei S, Ducci F, Discepoli N, Carmignani A, Tonetti M. Does enamel matrix derivative application provide additional clinical benefits in residual periodontal pockets associated with suprabony defects? A systematic review and meta-analysis of randomized clinical trials. J Clin Periodontol. 2014 Apr;41(4):377-86. doi: 10.1111/jcpe.12218. Epub 2014 Jan 22.

    PubMed 24329867
  • Sanz M, Herrera D, Kebschull M, Chapple I, Jepsen S, Beglundh T, Sculean A, Tonetti MS; EFP Workshop Participants and Methodological Consultants. Treatment of stage I-III periodontitis-The EFP S3 level clinical practice guideline. J Clin Periodontol. 2020 Jul;47 Suppl 22(Suppl 22):4-60. doi: 10.1111/jcpe.13290.

    PubMed 32383274
  • Papapanou PN, Wennstrom JL. The angular bony defect as indicator of further alveolar bone loss. J Clin Periodontol. 1991 May;18(5):317-22. doi: 10.1111/j.1600-051x.1991.tb00435.x.

    PubMed 2066446
  • Wachtel H, Schenk G, Bohm S, Weng D, Zuhr O, Hurzeler MB. Microsurgical access flap and enamel matrix derivative for the treatment of periodontal intrabony defects: a controlled clinical study. J Clin Periodontol. 2003 Jun;30(6):496-504. doi: 10.1034/j.1600-051x.2003.00013.x.

    PubMed 12795787
  • Simonelli A, Minenna L, Trombelli L, Farina R. Single flap approach with or without enamel matrix derivative in the treatment of severe supraosseous defects: a retrospective study. Clin Oral Investig. 2021 Nov;25(11):6385-6392. doi: 10.1007/s00784-021-03941-5. Epub 2021 Apr 14.

    PubMed 33855656
  • Trombelli L, Farina R, Franceschetti G, Calura G. Single-flap approach with buccal access in periodontal reconstructive procedures. J Periodontol. 2009 Feb;80(2):353-60. doi: 10.1902/jop.2009.080420.

    PubMed 19186978

Questions about this trial

What is this clinical trial studying?

A study testing viscoelastic gel containing polynucleotides and hyaluronic acid in people with Periodontitis and Gingival Recession, Localized, run by Azienda Unità Sanitaria Locale (A.U.S.L.) Ferrara, Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 1 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Interproximal gingival recession (iREC) (time frame: 6 months after surgical treatment of supraosseous defects). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06897085, which also lists 6 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Apr 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in